The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors-Reference-Cited by-同舟云学术

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

Published:2021-10-11 Issue:6 Volume:27 Page:921-931
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Escobar Miguel¹^ORCID,Castaman Giancarlo²^ORCID,Boix Santiago Bonanad³,Callaghan Michael⁴,Moerloose Philippe⁵,Ducore Jonathan⁶,Hermans Cédric⁷,Journeycake Janna⁸,Leissinger Cindy⁹,Luck James¹⁰,Mahlangu Johnny¹¹^ORCID,Miesbach Wolfgang¹²^ORCID,Mitha Ismail Haroon¹³,Négrier Claude¹⁴^ORCID,Quon Doris¹⁰,Recht Michael¹⁵¹⁶,Schved Jean François¹⁷,Shapiro Amy D.¹⁸^ORCID,Sidonio Robert¹⁹,Srivastava Alok²⁰^ORCID,Stasyshyn Oleksandra²¹,Vilchevska Kateryna V.²²,Wang Michael²³^ORCID,Young Guy²⁴²⁵^ORCID,Alexander W. Allan²⁶,Al‐Sabbagh Ahmad²⁷,Bonzo Daniel²⁷,Macie Christopher²⁸,Wilkinson Thomas A.²⁹,Kessler Craig³⁰

Affiliation:

1. Gulf States Hemophilia and Thrombophilia Center Houston Texas USA

2. Center for Bleeding Disorders and Coagulation Careggi University Hospital Florence Italy

3. University and Polytechnic Hospital La Fe Valencia Spain

4. Central Michigan University Detroit Michigan USA

5. Faculty of Medicine University of Geneva Geneva Switzerland

6. Hematology/Oncology Clinic University of California at Davis Sacramento California USA

7. Cliniques Saint‐Luc Université Catholique de Louvain Brussels Belgium

8. Oklahoma Bleeding and Clotting Disorders Center at OU Health Oklahoma City Oklahoma USA

9. Section of Hematology/Oncology Tulane University School of Medicine New Orleans Louisiana USA

10. Orthopaedic Hemophilia Treatment Center Los Angeles California USA

11. Hemophilia Comprehensive Care Center University of the Witwatersrand and National Health Laboratory Service Johannesburg South Africa

12. Goethe University Hospital Frankfurt Germany

13. Lakeview Hospital Benoni Gauteng South Africa

14. Edouard Herriot University Hospital Lyon France

15. American Thrombosis and Hemostasis Network Rochester New York USA

16. Oregon Health & Science University Portland Oregon USA

17. Haemophilia Treatment Centre University Hospital Montpellier Montpellier France

18. Indiana Hemophilia and Thrombosis Center Indianapolis Indiana USA

19. Aflac Cancer and Blood Disorders Center Emory University Atlanta Georgia USA

20. Christian Medical College Vellore Tamil Nadu India

21. Institute of Blood Pathology and Transfusion Medicine Lviv Ukraine

22. National Specialized Children's Hospital Okhmatdyt Kyiv Ukraine

23. Hemophilia and Thrombosis Center University of Colorado Aurora Colorado USA

24. Children's Hospital Los Angeles Los Angeles California USA

25. Keck School of Medicine University of Southern California Los Angeles California USA

26. Aoede Associates Athens Texas USA

27. LFB‐USA, Inc. Framingham Massachusetts USA

28. HEMA Biologics, LLC Louisville Kentucky USA

29. GLOVAL LLC Broomfield Colorado USA

30. Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington District of Columbia USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14419

Reference40 articles.

1. Overview of Inhibitors

2. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study

3. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

4. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor

5. Recombinant activated factor VII: 30 years of research and innovation

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

2. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

3. Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy;CPT: Pharmacometrics & Systems Pharmacology;2023-05-02

4. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors;Haemophilia;2022-04-27

5. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors;Haemophilia;2021-10-06